Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ILMN Stock Forecast 2025-2026
$90.26
Current Price
$14.16B
Market Cap
Buy 12
Hold 10
Sell 2
Wall St Analyst Ratings
Distance to ILMN Price Targets
+105.0%
To High Target of $185.00
+16.3%
To Median Target of $105.00
-22.4%
To Low Target of $70.00
ILMN Price Momentum
+2.4%
1 Week Change
+8.8%
1 Month Change
-14.2%
1 Year Change
-32.5%
Year-to-Date Change
-42.4%
From 52W High of $156.66
+31.4%
From 52W Low of $68.70
📊 TOP ANALYST CALLS
Did ILMN Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Illumina is one of their latest high-conviction picks.
Latest ILMN Stock Price Targets & Analyst Predictions
Based on our analysis of 34 Wall Street analysts, ILMN has a neutral consensus with a median price target of $105.00 (ranging from $70.00 to $185.00). The overall analyst rating is Buy (7.4/10). Currently trading at $90.26, the median forecast implies a 16.3% upside. This outlook is supported by 12 Buy, 10 Hold, and 2 Sell ratings.
The most optimistic forecast comes from David Westenberg at Piper Sandler, projecting a 105.0% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ILMN Analyst Ratings
12
Buy
10
Hold
2
Sell
ILMN Price Target Range
Low
$70.00
Average
$105.00
High
$185.00
Current: $90.26
Latest ILMN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ILMN.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jun 11, 2025 | Canaccord Genuity | Kyle Mikson | Hold | Maintains | $99.00 |
| May 20, 2025 | Stephens & Co. | Mason Carrico | Overweight | Reiterates | $105.00 |
| May 15, 2025 | Piper Sandler | David Westenberg | Overweight | Maintains | $185.00 |
| May 12, 2025 | Canaccord Genuity | Kyle Mikson | Hold | Maintains | $87.00 |
| May 12, 2025 | Morgan Stanley | Tejas Savant | Equal-Weight | Maintains | $100.00 |
| May 9, 2025 | JP Morgan | Julia Qin | Neutral | Maintains | $85.00 |
| May 9, 2025 | Guggenheim | Subbu Nambi | Buy | Maintains | $114.00 |
| Apr 29, 2025 | Canaccord Genuity | Kyle Mikson | Hold | Maintains | $92.00 |
| Apr 10, 2025 | Barclays | Luke Sergott | Underweight | Maintains | $77.00 |
| Apr 8, 2025 | RBC Capital | Conor McNamara | Outperform | Maintains | $112.00 |
| Apr 7, 2025 | Citigroup | Patrick Donnelly | Neutral | Maintains | $85.00 |
| Mar 12, 2025 | RBC Capital | Conor McNamara | Outperform | Maintains | $128.00 |
| Mar 11, 2025 | Canaccord Genuity | Kyle Mikson | Hold | Maintains | $115.00 |
| Mar 11, 2025 | Stephens & Co. | Mason Carrico | Overweight | Reiterates | $156.00 |
| Mar 5, 2025 | Baird | Catherine Ramsey | Neutral | Maintains | $90.00 |
| Mar 4, 2025 | Citigroup | Patrick Donnelly | Neutral | Maintains | $90.00 |
| Feb 11, 2025 | Morgan Stanley | Tejas Savant | Equal-Weight | Maintains | $136.00 |
| Feb 10, 2025 | Piper Sandler | David Westenberg | Overweight | Maintains | $190.00 |
| Feb 10, 2025 | Barclays | Luke Sergott | Underweight | Downgrade | $100.00 |
| Feb 7, 2025 | Canaccord Genuity | Kyle Mikson | Hold | Maintains | $135.00 |
Illumina, Inc. (ILMN) Competitors
The following stocks are similar to Illumina based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Illumina, Inc. (ILMN) Financial Data
Illumina, Inc. has a market capitalization of $14.16B with a P/E ratio of -11.7x. The company generates $4.34B in trailing twelve-month revenue with a -22.3% profit margin.
Revenue growth is -3.3% quarter-over-quarter, while maintaining an operating margin of +17.7% and return on equity of -23.8%.
Valuation Metrics
Market Cap
$14.16B
Enterprise Value
$15.53B
P/E Ratio
-11.7x
PEG Ratio
20.2x
Price/Sales
3.3x
Growth & Margins
Revenue Growth (YoY)
-3.3%
Gross Margin
+65.6%
Operating Margin
+17.7%
Net Margin
-22.3%
EPS Growth
-3.3%
Financial Health
Cash/Price Ratio
+8.7%
Current Ratio
1.9x
Debt/Equity
110.1x
ROE
-23.8%
ROA
+5.0%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Illumina, Inc. (ILMN) Business Model
About Illumina, Inc.
What They Do
Develops systems for genetic analysis and sequencing.
Business Model
Illumina generates revenue by selling integrated systems and tools for genomic research, primarily focusing on DNA sequencing and genetic mapping. Their products are essential for various applications in healthcare, including oncology, reproductive health, and diagnostics, allowing researchers and laboratories to perform high-precision genetic analysis.
Additional Information
Headquartered in San Diego, California, Illumina is a key player in the life sciences industry, driving innovation in personalized medicine and supporting initiatives in health, agrigenomics, and microbiology. Their cutting-edge technology significantly influences healthcare approaches and provides valuable insights into complex biological systems.
Company Information
Sector
Healthcare
Industry
Diagnostics & Research
Employees
8,970
CEO
Mr. Jacob Thaysen Ph.D.
Country
United States
IPO Year
2000
Website
www.illumina.comIllumina, Inc. (ILMN) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Tempus AI's Expanding Ties Boost Novel R&D Efforts and Market Reach
TEM expands major partnerships with AZN, ILMN, and PSNL, fueling AI-driven R&D and widening its precision medicine reach.
Jun 13, 2025
By Moumi Mondal
Analyst Blog
Latest News
Quick Summary
Infinity Bio closed an $8 million Series A financing round led by Illumina Ventures, with participation from other investors. The company also acquired assets from Serimmune, Inc.
Why It Matters
Infinity Bio's $8 million Series A funding signals strong investor confidence and potential growth in biotech. The acquisition of Serimmune enhances its capabilities, likely boosting future revenue prospects.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Illumina Inc. (NASDAQ: ILMN) released its annual CSR Report, highlighting efforts to enhance precision health access, promote sustainability, and uphold responsible business practices.
Why It Matters
Illumina's CSR report highlights its commitment to accessibility in precision health and sustainability, signaling potential long-term growth and positive public perception, which can influence stock performance.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
ILMN has launched PromoterAI, a tool designed to analyze noncoding genetic variants, with the goal of advancing rare disease diagnosis.
Why It Matters
ILMN's PromoterAI could enhance its position in the biotech sector, potentially leading to new revenue streams and increased market share in rare disease diagnostics, impacting stock performance.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Quick Summary
Illumina, Inc. (NASDAQ: ILMN) will participate in the Bernstein 41st Annual Strategic Decisions Conference Call on May 28, 2025, at 2:30 PM ET. CEO Jacob Thaysen will be present.
Why It Matters
Illumina's participation in the Bernstein Conference indicates its strategic priorities and potential growth areas, influencing investor sentiment and stock performance.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Illumina's TSO Comprehensive test receives broad payer reimbursement, enhancing access to genomic profiling. The company also introduces Pillar oncoReveal® CDx, expanding its oncology portfolio.
Why It Matters
Illumina's expanded oncology portfolio and broad payer reimbursement enhance its market position, potentially increasing revenue and patient access to precision therapies, positively impacting stock performance.
Source: PRNewsWire
Market Sentiment:
Neutral
Illumina unveils PromoterAI, a groundbreaking algorithm to accelerate insights for rare disease diagnosis
20 days ago
Quick Summary
Illumina Inc. (NASDAQ: ILMN) launched PromoterAI, an AI algorithm that identifies pathogenic genetic variants in noncoding regions, potentially impacting 6% of rare disease causes.
Why It Matters
Illumina's PromoterAI breakthrough enhances genetic research, potentially boosting demand for its products and services, impacting growth prospects and stock value positively.
Source: PRNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About ILMN Stock
What is Illumina, Inc.'s (ILMN) stock forecast for 2025?
Based on our analysis of 34 Wall Street analysts, Illumina, Inc. (ILMN) has a median price target of $105.00. The highest price target is $185.00 and the lowest is $70.00.
Is ILMN stock a good investment in 2025?
According to current analyst ratings, ILMN has 12 Buy ratings, 10 Hold ratings, and 2 Sell ratings. The stock is currently trading at $90.26. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ILMN stock?
Wall Street analysts predict ILMN stock could reach $105.00 in the next 12 months. This represents a 16.3% increase from the current price of $90.26. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Illumina, Inc.'s business model?
Illumina generates revenue by selling integrated systems and tools for genomic research, primarily focusing on DNA sequencing and genetic mapping. Their products are essential for various applications in healthcare, including oncology, reproductive health, and diagnostics, allowing researchers and laboratories to perform high-precision genetic analysis.
What is the highest forecasted price for ILMN Illumina, Inc.?
The highest price target for ILMN is $185.00 from David Westenberg at Piper Sandler, which represents a 105.0% increase from the current price of $90.26.
What is the lowest forecasted price for ILMN Illumina, Inc.?
Price targets from Wall Street analysts for ILMN are not currently available. The stock is trading at $90.26.
What is the overall ILMN consensus from analysts for Illumina, Inc.?
The overall analyst consensus for ILMN is neutral. Out of 34 Wall Street analysts, 12 rate it as Buy, 10 as Hold, and 2 as Sell, with a median price target of $105.00.
How accurate are ILMN stock price projections?
Stock price projections, including those for Illumina, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 19, 2025 5:30 AM UTC